Karvezide (Hydrochlorothiazide, Irbesartan)

Irbesartan blocks the angiotensin II type 1 receptor, preventing vasoconstriction and aldosterone‑mediated fluid retention. Hydrochlorothiazide acts on the distal convoluted tubule to inhibit sodium‑chloride reabsorption, increasing urine output and decreasing plasma volume. Together they provide complementary blood‑pressure‑lowering effects.

The appropriate dose of Karvezide is determined by the prescribing healthcare professional based on the patient’s clinical condition, response to therapy, and any concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Karvezide is generally not recommended during pregnancy because irbesartan may affect fetal development. The safety of hydrochlorothiazide in pregnancy is also uncertain. Breastfeeding mothers should consult their physician, as the drugs can be excreted in milk and may affect the infant.

To request Karvezide, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Karvezide combines an angiotensin II receptor blocker with a thiazide diuretic, offering dual mechanisms that can be more effective than monotherapy for many patients. Compared with single‑agent ACE inhibitors or calcium‑channel blockers, the combination may achieve target blood pressure with a single pill, potentially improving adherence.

Karvezide tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the label.

Karvezide is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a full glass of water and do not crush or chew it unless specifically instructed.

Serious adverse events can include severe dehydration, marked electrolyte disturbances (especially low potassium or sodium), acute kidney injury, angioedema, and profound hypotension. Patients should seek immediate medical attention if they experience swelling of the face or throat, rapid weight loss, dizziness, or persistent vomiting.

Karvezide is contraindicated in patients with known hypersensitivity to irbesartan, hydrochlorothiazide, or any component of the formulation. It should also be avoided in individuals with severe renal impairment, anuria, or those taking potassium‑sparing diuretics without close monitoring.